Biobetters From an Integrated Computational/Experimental Approach
Biobetters are new drugs designed from existing peptide or protein-based therapeutics by improving their properties such as affinity and selectivity for the target epitope, and stability against degradation. Computational methods can play a key role in such design problems—by predicting the changes...
Main Authors: | Serdar Kuyucak, Veysel Kayser |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-01-01
|
Series: | Computational and Structural Biotechnology Journal |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2001037016300952 |
Similar Items
-
Future of anti-VEGF: biosimilars and biobetters
by: Monika Kapur, et al.
Published: (2022-01-01) -
From Biologics to Biosimilars and Biobetters - Democratization of High-end Therapeutics
by: Santosh G Honavar
Published: (2021-01-01) -
An Omalizumab Biobetter Antibody With Improved Stability and Efficacy for the Treatment of Allergic Diseases
by: Peipei Liu, et al.
Published: (2020-11-01) -
Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters
by: HoUng Kim, et al.
Published: (2021-01-01) -
Development of L-Asparaginase Biobetters: Current Research Status and Review of the Desirable Quality Profiles
by: Larissa Pereira Brumano, et al.
Published: (2019-01-01)